RxSight, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this report unless otherwise stated.
EXHIBIT INDEX
| Exhibit · Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Number | Description | Form | File No. | Exhibit | Filing Date |
| 10.1*+ · Employment Letter, by and between the Registrant and Aziz Mottiwala, dated July 13, 2026. | |||||
| 10.2*+ · Change in Control Severance Agreement, by and between the Registrant and Aziz Mottiwala, dated as of July 13, 2026. | |||||
| 10.3*# · Collaboration Agreement, dated June 30, 2026, by and between the Registrant and Alcon Pharmaceuticals, Ltd. | |||||
| 10.4*+ · Consulting Agreement, dated June 1, 2026, by and between the Registrant and Systemize Partners, LLC. | |||||
| 10.5*+ · Amendment to Change in Control and Severance Agreement, dated April 17, 2026, by and between the Registrant and Ron Kurtz. | |||||
| 10.6*+ · Transition Employment Letter Agreement, dated July 13, 2026, by and between the Registrant and Ron Kurtz. | |||||
| 10.7*+ · Amended and Restated Change in Control Severance Agreement, dated July 13, 2026, by and between the Registrant and Ron Kurtz. | |||||
| 10.8+ | RxSight, Inc. 2026 Inducement Equity Incentive Plan. | S-8 | 333-297654 | Exhibit 4.2 | July 23, 2026 |
| 10.9+ | Form of 2026 Inducement Equity Incentive Plan Stock Option Agreement. | S-8 | 333-297654 | Exhibit 4.3 | July 23, 2026 |
| 10.10+ | Form of 2026 Inducement Equity Incentive Plan Restricted Stock Unit Agreement. | S-8 | 333-297654 | Exhibit 4.4 | July 23, 2026 |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as | ||||
| Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| 32.1† | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|---|---|
| 32.2† | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema with embedded linkbase documents. |
| 104 | Cover page Interactive Data File (embedded with the Inline XBRL document). |
- Filed herewith
- Indicates a management contract or compensatory plan or arrangement.
Portions of the exhibit were omitted pursuant to Regulation S-K Item 601(b)(10). The Registrant agrees to furnish to the SEC a copy of any omitted portions of the exhibit upon request.
† The certifications attached as Exhibit 32.1 and 32.2 that accompany this report are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of RxSight, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this report, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.